|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FUBP1 |
Gene summary for FUBP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FUBP1 | Gene ID | 8880 |
| Gene name | far upstream element binding protein 1 | |
| Gene Alias | FBP | |
| Cytomap | 1p31.1 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | B4DT31 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8880 | FUBP1 | A001-C-104 | Human | Colorectum | FAP | 2.92e-05 | -1.46e-01 | 0.0184 |
| 8880 | FUBP1 | A015-C-005 | Human | Colorectum | FAP | 1.19e-10 | -2.96e-01 | -0.0336 |
| 8880 | FUBP1 | A015-C-006 | Human | Colorectum | FAP | 1.77e-16 | -2.00e-01 | -0.0994 |
| 8880 | FUBP1 | A015-C-106 | Human | Colorectum | FAP | 1.27e-14 | -2.78e-01 | -0.0511 |
| 8880 | FUBP1 | A002-C-114 | Human | Colorectum | FAP | 2.21e-20 | -3.02e-01 | -0.1561 |
| 8880 | FUBP1 | A015-C-104 | Human | Colorectum | FAP | 9.05e-27 | -3.04e-01 | -0.1899 |
| 8880 | FUBP1 | A001-C-014 | Human | Colorectum | FAP | 5.44e-14 | -2.71e-01 | 0.0135 |
| 8880 | FUBP1 | A002-C-016 | Human | Colorectum | FAP | 1.37e-22 | -2.80e-01 | 0.0521 |
| 8880 | FUBP1 | A015-C-002 | Human | Colorectum | FAP | 2.87e-15 | -4.26e-01 | -0.0763 |
| 8880 | FUBP1 | A001-C-007 | Human | Colorectum | CRC | 9.41e-03 | -2.81e-01 | 0.1899 |
| 8880 | FUBP1 | A001-C-203 | Human | Colorectum | FAP | 7.63e-15 | -1.60e-01 | -0.0481 |
| 8880 | FUBP1 | A002-C-116 | Human | Colorectum | FAP | 1.48e-28 | -4.19e-01 | -0.0452 |
| 8880 | FUBP1 | A014-C-008 | Human | Colorectum | FAP | 6.42e-16 | -2.46e-01 | -0.191 |
| 8880 | FUBP1 | A018-E-020 | Human | Colorectum | FAP | 2.35e-24 | -4.44e-01 | -0.2034 |
| 8880 | FUBP1 | F034 | Human | Colorectum | FAP | 2.24e-18 | -3.70e-01 | -0.0665 |
| 8880 | FUBP1 | F072B | Human | Colorectum | FAP | 2.68e-07 | -2.10e-01 | 0.257 |
| 8880 | FUBP1 | CRC-1-8810 | Human | Colorectum | CRC | 2.52e-03 | -1.11e-01 | 0.6257 |
| 8880 | FUBP1 | CRC-3-11773 | Human | Colorectum | CRC | 1.75e-08 | -1.99e-01 | 0.2564 |
| 8880 | FUBP1 | LZE2T | Human | Esophagus | ESCC | 2.97e-10 | 9.22e-01 | 0.082 |
| 8880 | FUBP1 | LZE4T | Human | Esophagus | ESCC | 2.02e-10 | 4.38e-01 | 0.0811 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FUBP1 | SNV | Missense_Mutation | novel | c.997N>G | p.Gln333Glu | p.Q333E | Q96AE4 | protein_coding | tolerated(0.54) | benign(0.055) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| FUBP1 | SNV | Missense_Mutation | c.32N>A | p.Ser11Tyr | p.S11Y | Q96AE4 | protein_coding | deleterious(0.01) | possibly_damaging(0.496) | TCGA-A2-A0YD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| FUBP1 | SNV | Missense_Mutation | c.1849G>C | p.Glu617Gln | p.E617Q | Q96AE4 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| FUBP1 | SNV | Missense_Mutation | c.1902N>A | p.Met634Ile | p.M634I | Q96AE4 | protein_coding | tolerated_low_confidence(0.4) | benign(0) | TCGA-AN-A0AR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FUBP1 | SNV | Missense_Mutation | novel | c.1741G>A | p.Asp581Asn | p.D581N | Q96AE4 | protein_coding | deleterious(0.03) | probably_damaging(0.989) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| FUBP1 | insertion | Frame_Shift_Ins | novel | c.88_89insT | p.Ala30ValfsTer19 | p.A30Vfs*19 | Q96AE4 | protein_coding | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| FUBP1 | insertion | Frame_Shift_Ins | novel | c.87_88insATTGCTGTTCTTCTATACACAATAAG | p.Ala30IlefsTer33 | p.A30Ifs*33 | Q96AE4 | protein_coding | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| FUBP1 | deletion | Frame_Shift_Del | novel | c.660delT | p.Met221Ter | p.M221* | Q96AE4 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| FUBP1 | SNV | Missense_Mutation | c.32N>T | p.Ser11Phe | p.S11F | Q96AE4 | protein_coding | deleterious(0.01) | benign(0.4) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| FUBP1 | SNV | Missense_Mutation | novel | c.801N>C | p.Glu267Asp | p.E267D | Q96AE4 | protein_coding | tolerated(0.83) | benign(0.003) | TCGA-EA-A43B-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |